Skip to main content

ADCLEC.syn1 CAR T cells

ADCLEC.syn1 in People With Acute Myeloid Leukemia

  • RegistryNCT05748197
  • PhasePhase 1
  • StatusRecruiting
  • ConditionAcute Myeloid Leukemia
  • SponsorMemorial Sloan Kettering Cancer Center
How ADCLEC.syn1 CAR T cells worksNCT057481971 min

What the film says

Read the transcript

CAR T cells have not worked well in acute myeloid leukemia, for a stubborn reason: the markers on AML cells also sit on the normal stem cells that make blood. Hit one, and you risk wiping out the marrow.

The idea: require two markers before the cells fire.

At Memorial Sloan Kettering, a patient's T cells receive a deliberately weakened receptor for one AML marker, ADGRE2, and a second receptor for another, CLEC12A, that only supplies the boost. Leukemia stem cells carry both; normal blood stem cells mostly do not. In mice, the design cleared AML and prevented escape while sparing normal blood formation.

A dose-finding study in adults with relapsed or refractory AML. Jae Park leads it. Public record; not medical advice.

Sources behind this film

The drug

What is being tested.

There are 4 planned flat-dose levels: 25 × 10^6, 75 × 10^6 , 225 × 10^6 , and 450 × 10^6 CAR T cells and 1 de-escalation dose: 10 × 10^6 CAR T cells.

Fludarabine 30 mg/m2 daily for 3 days and cyclophosphamide 500 mg/m2 daily for 3 days.

The study

How the trial runs.

The purpose of this study is to test the safety of ADCLEC.syn1 CAR T cells in people with relapsed or refractory AML. The researchers will try to find the highest dose of ADCLEC.syn1 CAR T cells that causes few or mild side effects in participants. Once the researchers find this dose, it will test it in a new group of participants to see if it is effective in treating their relapsed/refractory AML.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Age ≥18 years of age at the time of signing informed consent.
  • Patients must have R/R AML. The following disease status will be eligible for the study:
  • a. Refractory AML is defined as failure to achieve a CR, CRh or CRi after one of the following regimens: i. At least one course of standard intensive induction chemotherapy (e.g., 7+3, MEC, HiDAC, etc.) or hypomethylating agent (HMA) or low dose cytarabine-based combination regimen including but not limited to venetoclax (e.g. venetoclax in combination with azacytidine, decitabine or cytarabine) ii. Four cycles of HMA monotherapy b. Relapsed AML is defined the appearance of ≥5% blasts in the bone marrow or peripheral blood at any time after achieving a CR, CRh, or CRi.
  • ECOG performance status 0 or 1.
  • Subjects must have a suitable stem cell donor identified who may donate cells in the event that the subject needs to undergo an allogeneic HSCT for rescue from prolonged marrow aplasia.
  • Donor may be from related or unrelated matched source, haplo or cord, and must be found to be suitable according to the institution's standard criteria.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.